RxDoctor Payments Data

Valerie Cooper

Nurse Practitioner · Roseburg, ORNPI 1144822644

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,494 of the $1,703 with a category attached, or 87.7%. It is spread thinly across 32 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $618 and has fallen 68.5% since, to $195 in 2025. Among nurse practitioner clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,703in general payments, 2019–2025

Across 79 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$183
  • Amgen$113
  • Seagen Inc.$110
  • Astellas Pharma US Inc$99
  • AstraZeneca$91
  • Sanofi$90
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$1,49488%
  • Education$20912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,703 in reported general payments places this provider in the 95th percentile of 997 nurse practitioner providers in Oregon.

See all nurse practitioner providers in Oregon

Medicare billing

Part B allowed, 2024
$145,341
Medicare patients
371
Services billed
43,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine12$83,907
XareltoRivaroxaban26$17,852
EliquisApixaban16$11,071
Hydroxyurea39$679
Letrozole33$517
Anastrozole14$370
Oxycodone Hcl23$365
Ondansetron OdtOndansetron21$262
Omeprazole43$217
Potassium Chloride30$192
Tamsulosin Hcl14$96
Metoclopramide Hcl19$86
Tramadol Hcl16$72
Furosemide17$47
Amitriptyline Hcl11$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPromacta$183$83,90712 claims
Johnson & JohnsonXarelto$86$17,85226 claims
PfizerEliquis$66$11,07116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 997 nurse practitioner providers in Oregon.

Other nurse practitioner in Roseburg

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →